Stay updated with breaking news from Commodore Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results
19.04.2023 - EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2022 financial results and ...
EQS-News: ABIVAX / Key word(s): Annual ResultsAbivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price […]